Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.50 |
| ▸ | FDPS | P14324 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3480225 | 0.93 | HSD17B2 (0.54) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL8320092 | 0.90 | HSD17B2 (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171425 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL31474383 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171427 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL7718554 | 0.88 | HSD17B2 (0.59) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171436 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11245624 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL2308139 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171409 | 0.88 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536184-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8536184-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-09-17 | — | — | US | disclosed |
| US-8367824-B2 | Reacting anthranilic acid with formic acid compound in presence of a catalyst and solvent | UBE INDUSTRIES LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| US-20100240893-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-7709640-B2 | Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-05-04 | — | — | US | disclosed |
| US-20050145550-A1 | Automatic chemical injection system for water recreational apparatus | CALIFORNIA ACRYLIC INDUSTRIES | 2005-07-07 | — | — | US | disclosed |
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | UBE INDUSTRIES, LTD. (JP) | 2005-04-14 | — | — | US | disclosed |
| EP-1477481-A1 | PROCESS FOR PRODUCING QUINAZOLIN-4-ONE DERIVATIVE | Ube Industries, Ltd. (JP) | 2004-11-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050080262-A1 | Process for producing quinazolin-4-one derivative | NQO2, SDHA, CYP3A4 | HSD17B2 2746/4885NPC1 4721/4885RAB9A 777/4885 |
| US-20100240893-A1 | NITROGENOUS HETEROCYCLIC COMPOUNDS AND PROCESS FOR MAKING NITROGENOUS HETEROCYCLIC COMPOUNDS AND INTERMEDIATES THEREOF | NME1, NME2, TNNI3K | HSD17B2 2979/4885NPC1 1699/4885RAB9A 2215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.